BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34643617)

  • 1. Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan.
    Chen BF; Tsai YF; Huang CC; Hsu CY; Lien PJ; Wang YL; Lin YS; Feng CJ; King KL; Chiu JH; Chau GY; Tseng LM
    J Chin Med Assoc; 2022 Feb; 85(2):190-197. PubMed ID: 34643617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Chao TC; Lai JI; Tseng LM; Huang CC
    Breast Cancer; 2024 Mar; 31(2):217-227. PubMed ID: 38070067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtypes and the risk of local and regional relapse.
    Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
    J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
    Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
    Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
    Kwon MJ; Lee SB; Han J; Lee JE; Lee JW; Gong G; Beitsch PD; Nam SJ; Ahn SH; Nam BH; Shin YK
    PLoS One; 2018; 13(11):e0207155. PubMed ID: 30462685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
    Ye J; Wang W; Xin L; Owen S; Xu L; Duan X; Cheng Y; Zhang H; Zhang S; Li T; Liu Y
    Anticancer Res; 2017 Aug; 37(8):4549-4556. PubMed ID: 28739751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
    BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
    Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
    Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
    [No Abstract]   [Full Text] [Related]  

  • 15. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
    Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
    Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012.
    García Fernández A; Chabrera C; García Font M; Fraile M; Gónzalez S; Barco I; González C; Cirera L; Veloso E; Lain JM; Pessarrodona A; Giménez N
    Tumour Biol; 2013 Aug; 34(4):2349-55. PubMed ID: 23605321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of molecular classification of breast cancer on the safety of breast-conserving surgery].
    Li Y; Mu L; Ruan YX; Wang YT; Zhang D; Zhou H; Wang X
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):341-346. PubMed ID: 29860760
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
    Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
    J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of young age on outcome in early stage breast cancer.
    Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer.
    Davey MG; Ryan ÉJ; McAnena PF; Boland MR; Barry MK; Sweeney KJ; Malone CM; McLaughlin RJ; Lowery AJ; Kerin MJ
    Surg Oncol; 2021 Jun; 37():101531. PubMed ID: 33545657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.